Ticker Details
Amicus Therapeutics, Inc. Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines.
IPO Date:	May 31, 2007
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.5B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.23 | 2.63%
Avg Daily Range (30 D):	$0.02 | 0.11%
Avg Daily Range (90 D):	$0.09 | 0.92%

Institutional Daily Volume
Avg Daily Volume:	1.66M
Avg Daily Volume (30 D):	6.13M
Avg Daily Volume (90 D):	8.01M

Trade Size
Avg Trade Size (Sh.):	156
Avg Trade Size (Sh.) (30 D):	399
Avg Trade Size (Sh.) (90 D):	295

Institutional Trades
Total Institutional Trades:	8,399
Avg Institutional Trade:	$2.96M
Avg Institutional Trade (30 D):	$3.59M
Avg Institutional Trade (90 D):	$3.41M
Avg Institutional Trade Volume:	.26M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$3.77M
Avg Closing Trade (30 D):	$6.1M
Avg Closing Trade (90 D):	$8.17M
Avg Closing Volume:	340.85K

News

Feb 19, 2026 @ 11:30 PM Halper Sadeh LLC is Investigating Whether RAPT, CT... Source: Halper Sadeh Llc

Feb 19, 2026 @ 9:48 PM $HAREHOLDER ALERT: The M&A Class Action Firm Encou... Source: Monteverde & Associates Pc

Jan 7, 2026 @ 7:27 PM Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG ... Source: Halper Sadeh Llc

Jan 6, 2026 @ 7:58 PM Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG ... Source: Halper Sadeh Llc

Dec 23, 2025 @ 8:19 PM BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Inve... Source: Brodsky & Smith

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.09	$	$-.09
Diluted EPS	$-.09	$	$-.09
Revenue	$634.21M	$185.21M	$634.21M
Gross Profit	$561.28M	$158.67M	$561.28M
Net Income / Loss	$-27.11M	$1.69M	$-27.11M
Operating Income / Loss	$32.79M	$15.95M	$32.79M
Cost of Revenue	$72.93M	$26.55M	$72.93M
Net Cash Flow	$.6M	$23.46M	$.6M
PE Ratio